A short-lived antibody that activates the peripheral immune system instead of the brain shows promising results in a Phase 1b clinical trial for Alzheimer's disease.
Background
Limitations of traditional therapies and the re-evaluation of the peripheral immune system
Alzheimer's disease (AD) drug development has long focused on directly targeting amyloid-beta (Aβ) protein in the brain. Lecanemab and Donanemab, recently approved, are representative examples, but they are associated with the risk of Amyloid-Related Imaging Abnormalities (ARIA), which cause brain swelling and microhemorrhage. Furthermore, the need for continuous drug administration poses a significant physical and financial burden on patients.
For the past 25 years, the research team led by Professor Michal Schwartz at the Weizmann Institute of Science has demonstrated that the peripheral immune system plays an essential role in maintaining brain health and repairing damage. Instead of directly targeting the brain, the researchers developed a novel strategy to activate immune cells outside the brain to remove toxic substances. IBC-Ab002 is an antibody drug candidate developed based on this mechanism. It targets programmed death-ligand 1 (PD-L1), a protein that inhibits the activity of immune cells, to induce the influx of immune cells into the brain.
Key Findings
Safety and biomarker improvement trends of short-lived antibodies
According to the results of the Phase 1b clinical trial (IBC-01-01) published in Nature Medicine, IBC-Ab002 showed safety and tolerability in patients with early Alzheimer's disease. This double-blind clinical trial, conducted at 11 institutions in the United Kingdom, Israel, and the Netherlands, involved 40 patients with mild cognitive impairment or early dementia, with confirmed amyloid accumulation in cerebrospinal fluid (CSF). They were randomly assigned to either the active drug group or the placebo group in a 3:1 ratio.
The clinical researchers divided the patients into five cohorts and increased the dose to 1, 3, 6, 15, and 30 mg/kg while observing for adverse reactions. The patients received a total of four intravenous infusions at 12-week intervals. The results showed that no serious adverse events or ARIA cases related to the drug were observed, even in the 30 mg/kg dose group.
To avoid the autoimmune side effects seen with existing immune checkpoint inhibitors, the researchers shortened the drug's half-life to approximately 4 days and removed the Fc effector function, which induces cytotoxicity. Thanks to this molecular design, the peripheral immune system is activated only temporarily without continuous stimulation. In addition, in the group of patients who received the highest dose of 30 mg/kg, there was a trend of decreased levels of neurogranin, which indicates synaptic damage, and total tau (t-Tau) and phosphorylated tau 181 (pTau181), which are markers of neuronal damage.
Significance and Prospects
Potential of a new target strategy and remaining challenges
This clinical study demonstrates a new paradigm for the treatment of Alzheimer's disease. The mechanism of training peripheral immune cells to enter the brain instead of forcing large antibodies that are difficult to pass through the blood-brain barrier into the brain has the advantage of safety. By administering short-lived antibodies intermittently, the risk of normal tissue damage due to chronic immune activation is reduced.
However, the Phase 1b trial is limited to 40 patients and is not a stage to confirm the therapeutic efficacy of the drug. To confirm whether it can actually slow down or stop cognitive decline, a Phase 2 and Phase 3 trial with a larger number of patients and long-term follow-up is needed. Future clinical studies are expected to focus on overcoming individual differences in patient immune status.
Nature Medicine, Published online: 15 July 2026; doi:10.1038/s41591-026-04547-8A phase 1b trial shows that IBC-Ab002, a short-lived antibody that intermittently activates the peripheral immune system, is safe and well tolerated with trends in biomarkers in people with early Alzheimer’s disease, supporting further clinical development.
This research provides a new treatment option for Alzheimer's patients who have hesitated to receive treatment due to the risk of side effects. In particular, it may be a useful option for patients with the APOE4 gene, who have a very high risk of ARIA when treated with amyloid-targeting antibodies. IBC-Ab002 is relatively safe to administer because it does not directly cause brain inflammation and helps macrophages, which act as scavengers in the body, enter the brain. In addition, the periodic treatment administered once every 12 weeks helps improve the daily life and convenience of patients compared to existing treatments that require hospital visits every week or every other week. Furthermore, it is expected to bring about positive changes in terms of reducing the economic burden on medical institutions and improving the convenience of the dispensing system.